Therapy with tPA Found to Be Safe in SCD Patients Who Have a Stroke
Patients who suffered a stroke and have sickle cell disease (SCD) can safely receive lytic therapy with tissue plasminogen activator (tPA), according to new research. The study, “Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke,” was published in…